|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:PMDA
gptkb:FDA
|
|
gptkbp:ATCCode
|
N07XX13
|
|
gptkbp:brand
|
gptkb:Radicava
gptkb:Radicut
|
|
gptkbp:CASNumber
|
89-25-8
|
|
gptkbp:chemicalFormula
|
C10H10N2O
|
|
gptkbp:developedBy
|
gptkb:Japan
|
|
gptkbp:discoveredBy
|
gptkb:Mitsubishi_Tanabe_Pharma
|
|
gptkbp:hasInChIKey
|
QELUYTUMUWHWMC-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
CC1=NN(C(=O)C1)c2ccccc2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Edaravone
|
|
gptkbp:IUPACName
|
3-methyl-1-phenyl-2-pyrazolin-5-one
|
|
gptkbp:KEGGID
|
D01244
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
free radical scavenger
|
|
gptkbp:molecularWeight
|
174.20 g/mol
|
|
gptkbp:PubChem_CID
|
4021
CHEMBL1201192
DB12243
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
headache
allergic reactions
gait disturbance
bruising
skin inflammation
|
|
gptkbp:UNII
|
QX9Y1D02F0
|
|
gptkbp:usedFor
|
amyotrophic lateral sclerosis
acute ischemic stroke
|
|
gptkbp:year_of_approval_(Japan)
|
2001
|
|
gptkbp:year_of_approval_(US)
|
2017
|
|
gptkbp:bfsParent
|
gptkb:Mitsubishi_Tanabe_Pharma_Corporation
gptkb:MCI-186
|
|
gptkbp:bfsLayer
|
7
|